TempV

Aus coViki
Version vom 15. September 2021, 14:09 Uhr von Ossip Groth (Diskussion | Beiträge)
(Unterschied) ← Nächstältere Version | Aktuelle Version (Unterschied) | Nächstjüngere Version → (Unterschied)
Wechseln zu: Navigation, Suche


34012335 2021. Vaccine against SARS-CoV-2: Challenges and considerations.
33933606 2021. COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death.
33936347 2021. Immunoinformatics Identification of B- and T-Cell Epitopes in the RNA-Dependent RNA Polymerase of SARS-CoV-2.
34055430 2021. Exacerbating Guillain-Barre Syndrome Eight Days after Vector-Based COVID-19 Vaccination.
34076125 2021. Vacinas: Da Saude Publica ao Big Business.
33938790 2021. Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis.
34053731 2021. Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines.
33824804 2021. Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect.
33968515 2021. Rapid Development of Clinically Symptomatic Radiation Recall Pneumonitis Immediately Following COVID-19 Vaccination.
34084669 2021. Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine.
33996313 2021. BCG Scar Local Skin Inflammation as a Novel Reaction Following mRNA COVID-19 Vaccines in Two International Healthcare Workers.
33845349 2021. Supply and delivery of vaccines for global health.
34000712 2021. Focal onset non-motor seizure following COVID-19 vaccination: A mere coincidence?
33991805 2021. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India.
33888439 2021. Myocardial infarction after COVID-19 vaccination-casual or causal?
33962903 2021. Imaging of Oxford/AstraZeneca(R) COVID-19 vaccine-induced immune thrombotic thrombocytopenia.
34064509 2021. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
34073536 2021. COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis.
34070341 2021. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
34075362 2021. The Uro-oncology Patient and Vaccination Against SARS-CoV-2.
34047271 2021. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.
34018481 2021. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.
33959579 2021. Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D.
33903149 2021. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
34011137 2021. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia.
34026475 2021. Surmounting inherent challenges in healthcare service delivery for effective procurement and distribution of COVID-19 vaccines; A developing country context.
34103937 2021. Vaccination and the Prevention of Communicable Diseases in Healthcare Settings: Lessons from the Covid-19 Pandemic.
33855127 2021. A Higher Number of Covid19 Cases and Fatalities in Israel Phased With the Start of the Mass Vaccination.
33916122 2021. Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting.
33968610 2021. Guillain-Barre syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association.
33908359 2021. Problematic Covid-19 vaccine trials in times of vaccine nationalism.
33908358 2021. Placebo-controlled trials of Covid-19 vaccines - Are they still ethical?
33908357 2021. Testing vaccines in the time of Covid: The changing landscape.
33908356 2021. "No" to placebo-controlled trials of Covid-19 vaccines.
33908354 2021. The continued use of placebo arms in COVID-19 vaccine trials does not adequately protect the well-being of participants.
33908353 2021. Placebo control in Covid-19 trials: A missed opportunity for international guidance.
33908352 2021. Trials for second generation Covid-19 vaccines: Revisiting the debate over placebo use in developing country clinical trials.
33908351 2021. Placebo in new Covid-19 vaccine trials: data quality prioritised over participants' rights.
33908350 2021. Ethical limits to placebo use and access to Covid-19 vaccines as a human right.
34099338 2021. Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine.
33361645 2021. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.
33361644 2021. The quest continues for perfect COVID-19 vaccine.
33938416 2021. "Original antigenic sin": A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants.
33963523 2021. Coincidental SARS-CoV-2 infection and mRNA vaccination: a case report addressing the most important clinical questions.
34066995 2021. Facial and Oral Manifestations Following COVID-19 Vaccination: A Survey-Based Study and a First Perspective.
34047035 2021. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
33826780 2021. Harnessing the nursing contribution to COVID-19 mass vaccination programmes: Addressing hesitancy and promoting confidence.
34048595 2021. Early success of COVID-19 vaccines in nursing homes: Will it stick?
33955567 2021. The BNT162b2 vaccine is associated with lower new COVID-19 cases in nursing home residents and staff.
33861873 2021. Short-term impact of nursing home SARS-CoV-2 vaccinations on new infections, hospitalizations, and deaths.
33861871 2021. Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers.
34048614 2021. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?
34021625 2021. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy.
33982814 2021. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine.
33982318 2021. Recurrent injection-site reactions after incorrect subcutaneous administration of a COVID-19 vaccine.
34058038 2021. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine.
34077572 2021. Immune thrombocytopenic purpura associated with COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine.
33914966 2021. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2.
33914958 2021. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report.
33899974 2021. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance.
33834563 2021. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series.
33905793 2021. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
33989631 2021. Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
34008027 2021. Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials.
34007981 2021. Behind the Scenes Heroes: the COVID-19 Vaccine Data and Safety Monitoring Board.
34007998 2021. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report.
34003413 2021. Coronavirus Disease-19 Vaccines Best Reflect Effective Pharmaceuticals.
34000472 2021. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
34032902 2021. Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report.
34023956 2021. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis.
33864125 2021. Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.
33844056 2021. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
33762164 2021. A Shot at Inclusion: Reconsidering Categorical Exclusion of Hospice Patients from COVID Vaccine Allocation.
33941938 2021. Medical and ethical issues related to COVID-19 vaccine.
34059124 2021. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech).
33321139 2021. Addressing the Cold Reality of mRNA Vaccine Stability.
34053350 2021. 2019 Novel Coronavirus Vaccination among Post-graduate Residents and Fellows.
33945346 2021. Assessing the long-term safety and efficacy of COVID-19 vaccines.
34018298 2021. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology.
33931935 2021. Vaccine-induced immune thrombotic thrombocytopenia: Consider IVIG batch in the treatment.
33909350 2021. An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination.
33904251 2021. Post-adenoviral-based COVID-19 vaccines thrombosis: A proposed mechanism.
33877737 2021. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine.
33877735 2021. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
33973336 2021. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination.
34050372 2021. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
34002240 2021. Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of inactivated COVID-19 vaccine Covaxin.
34047765 2021. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
34090624 2021. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
33890680 2021. Parsonage Turner syndrome after COVID-19 vaccination.
33851437 2021. Post COVID-19 vaccine small fiber neuropathy.
34036651 2021. SARS-CoV-2 mRNA vaccine-associated fixed drug eruption.
34085933 2021. Administration of the Comirnaty(R) Vaccine in a Fractional Regimen in Two Patients with Immediate Acute Urticaria after the First Dose.
34035134 2021. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
34035133 2021. Ischaemic stroke can follow COVID-19 vaccination but is much more common with COVID-19 infection itself.
33741644 2021. FDG Avid Axillary Lymph Nodes After COVID-19 Vaccination.
33893188 2021. Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.
33820864 2021. Reactive Axillary Lymphadenopathy to COVID-19 Vaccination on (18)F-FDG PET/CT.
33658251 2021. Intramuscular Injections for COVID-19 Vaccinations.
34074678 2021. The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know.
34076338 2021. The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters.
33904859 2021. Israel's Real-life Evidence That Vaccine Can Prevent Severe COVID-19.
33856406 2021. Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose.
33835153 2021. Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations: Lessons Learned From Functional Neurological Disorder.
33983372 2021. COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.
33974494 2021. Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
33731936 2021. Innovators target vaccines for variants and shortages in global South.
33972767 2021. A global database of COVID-19 vaccinations.
34021288 2021. 'It's a minefield': COVID vaccine safety poses unique communication challenge.
34012131 2021. Mix-and-match COVID vaccines trigger potent immune response.
33963317 2021. Pfizer COVID vaccine protects against worrying coronavirus variants.
33948031 2021. China's COVID vaccines are going global - but questions remain.


34051441 2021. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
33829986 2021. Postvaccination COVID-19 among Healthcare Workers, Israel.
34034858 2021. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
34057040 2021. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.
34025118 2021. SARS-CoV-2 y los mitos sobre la vacunacion.
33858709 2021. Taquicardia como efecto adverso no descrito en la vacuna Comirnaty(c) (vacuna COVID-19 mRNA BNT162b2 de Pfizer-BioNTech): descripcion de 3 casos con antecedentes de SARS-CoV-2.
33968462 2021. COVID-19 Vaccine Allocation: Modeling Health Outcomes and Equity Implications of Alternative Strategies.
33898075 2021. Coronavirus Variants-Will New mRNA Vaccines Meet the Challenge?
34001753 2021. Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.
34058493 2021. Estimated effect of COVID-19 vaccine in people with epilepsy.
33948639 2021. COVID-19 vaccine induced prothrombotic immune thrombocytopenia.
33928898 2021. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.
33598436 2020. COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy.
33842684 2021. Temporal Relation Between Second Dose BNT162b2 mRNA Covid-19 Vaccine and Cardiac involvement in a Patient with Previous SARS-COV-2 Infection.
33368867 2021. Change in ectopic pregnancy presentations during the covid-19 pandemic.
33992761 2021. Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia.
34022331 2021. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals.
34022329 2021. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.
33992763 2021. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
34044114 2021. Acute abducens nerve palsy following COVID-19 vaccination.
33866033 2021. COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach.
33864927 2021. "COVID Arm": Very delayed large injection site reactions to mRNA COVID-19 vaccines.
33831618 2021. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
33892171 2021. The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.
33838847 2021. PEG skin testing for COVID-19 vaccine allergy.
33838846 2021. Reply to "PEG skin testing for COVID-19 allergy".
33838206 2021. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
33878412 2021. Response to comment on "An evidence-based guide to SARS-Cov-2 vaccination of patients on immunotherapies in dermatology."
33744352 2021. Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology".
34057580 2021. PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature.
34006471 2021. COVID-19 mRNA vaccines.
33994322 2021. The challenge of emerging SARS-CoV-2 mutants to vaccine development.
34034958 2021. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
34059088 2021. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
34001183 2021. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
34088334 2021. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination.
33964372 2021. Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"
34052253 2021. High acceptance rate of COVID-19 vaccination in liver transplant recipients.
34048861 2021. Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
34026245 2021. Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers.
34026244 2021. Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom.
33872188 2021. Returning to a Normal Life via COVID-19 Vaccines in the United States: A Large-scale Agent-Based Simulation Study.
33907723 2021. Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients.
33972817 2021. TClustVID: A novel machine learning classification model to investigate topics and sentiment in COVID-19 tweets.
34038996 2021. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
33285121 2021. Coronavirus vaccine? Join the queue.
34048723 2021. SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
33961810 2021. Time for the ethical management of COVID-19 vaccines.
33910219 2021. Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood.
33991381 2021. Coronavirus disease 2019 (COVID-19) vaccines: A concise review.
33978308 2021. Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine.
33844386 2021. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine.
33844797 2021. Vacunas SARS CoV-2, estudios en fase III.
34108737 2021. Posible efecto del <> en la vacunacion frente a las nuevas variantes del SARS-CoV-2.
34108736 2021. Covid-19, guillain-barre y vacuna. Una mezcla peligrosa.
33994339 2021. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19.
34103407 2021. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.
33931567 2021. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.
34103125 2021. La vaccination des soignants contre la Covid-19.
33962725 2021. Covid-19 et grippe : intention de vaccination chez les professionnels de sante.
34083026 2021. Atypical thrombosis associated with VaxZevria(R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.
34049688 2021. Efficacy of COVID-19 vaccines: From clinical trials to real life.
33892936 2021. Thrombotic events after AstraZeneca vaccine: What if it was related to dysfunctional immune response?
33858693 2021. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy.
33878469 2021. Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination.
34029848 2021. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.
34018389 2021. Dodsfall i sykehjem etter covid-19-vaksine.
33624982 2021. Koronavaksinering av kreftpasienter.
33928772 2021. Fatal hjerneblodning etter covid-19-vaksine.
33928773 2021. Dyp venetrombose mer enn to uker etter vaksinering mot covid-19.
33876625 2021. Private klinikker bor kunne sette covid-19-vaksiner.
34049359 2021. COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford-AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India.
33737163 2021. Blunting COVID-19's negative impact: Lessons from Israel's vaccination campaign.
34051353 2021. The story behind Chile's rapid rollout of COVID-19 vaccination.
34102015 2021. What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective.
33864857 2021. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System.
33846043 2021. Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
33846042 2021. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
33888324 2021. Developing standard safety outcomes for COVID-19 vaccines.
33896663 2021. Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
34092431 2021. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
34092429 2021. Myocarditis following COVID-19 mRNA vaccination.
34088506 2021. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
34059373 2021. The first Chinese national standards for SARS-CoV-2 neutralizing antibody.
34039497 2021. An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
34070152 2021. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques.
34069852 2021. Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants.
34067511 2021. Accidental Interruption of the Cold Chain for the Preservation of the Moderna COVID-19 Vaccine.
34067955 2021. The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19.
34066016 2021. Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2.
34064613 2021. Immune Response to COVID-19 mRNA Vaccine-A Pilot Study.
34068677 2021. Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model.
33918841 2021. Strategies for Immunomonitoring after Vaccination and during Infection.
33918085 2021. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis.
33918072 2021. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines.
33916489 2021. The COVID-19 Vaccines: Recent Development, Challenges and Prospects.
33946748 2021. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination.
33925650 2021. Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities-An Agent-Based Modeling Evaluation.
33925526 2021. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.
33864049 2021. COVID vaccines and blood clots: five key questions.
33854229 2021. India's COVID-vaccine woes - by the numbers.
33893760 2021. Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
33320052 2021. COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission.
33833099 2021. The story behind COVID-19 vaccines.
33888633 2021. Partial immunity and SARS-CoV-2 mutations-Response.
33888632 2021. Partial immunity and SARS-CoV-2 mutations.
33859017 2021. The dream vaccine.
33859010 2021. Vaccine link to serious clotting disorder firms up.
33971677 2021. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation.
34049360 2021. Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination.
34028386 2021. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept.
33966023 2021. Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients.


33934060 2021. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).
34021394 2021. [(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination.
33966088 2021. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
34020833 2021. EBCOG position statement on COVID-19 vaccination for pregnant and breastfeeding women.
34097044 2021. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
34061205 2021. The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic.
34061203 2021. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.
33886507 2021. Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus.
33908897 2021. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
33894163 2021. COVID-19 vaccines: building and maintaining confidence.
33887255 2021. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
33977283 2021. COVID-19 vaccines in older adults with cancer: a Young International Society of Geriatric Oncology perspective.
34087093 2021. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
33887209 2021. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
34019801 2021. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
34051181 2021. Vaccine development lessons between HIV and COVID-19.
34000242 2021. The rocky road to universal COVID-19 vaccination.
33887207 2021. COVID-19 herd immunity by immu" width="940" height="350" frameborder="0" scrolling="auto"> tion: are children in the herd?
33743847 2021. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
33930321 2021. Symptom study app provides real-world data on COVID-19 vaccines.
33930320 2021. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
33861968 2021. SARS-CoV-2 incidence and vaccine escape.
33357392 2021. Equitable distribution of COVID-19 vaccines.
33338440 2021. Concerns and motivations about COVID-19 vaccination.
34051887 2021. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
33887210 2021. Recombinant protein vaccines against SARS-CoV-2.
33887208 2021. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
33306980 2021. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
33899038 2021. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room.
33870240 2021. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2.
34087152 2021. COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma.
34087120 2021. COVID-19 vaccines in patients with cancer.
33930324 2021. Cancer and COVID-19 vaccines: a complex global picture.
33930323 2021. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
33991482 2021. Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial.
33954296 2021. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications.
33870258 2021. Reply to "Focusing COVID-19 vaccinations on elderly and high-risk people".
33961878 2021. COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses.
33915160 2021. Optimal allocation of limited vaccine to control an infectious disease: Simple analytical conditions.
34014913 2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
34014911 2021. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021.
34014909 2021. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
33914723 2021. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
33914721 2021. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021.
33914720 2021. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021.
33867582 2021. COVID-19-Impfstoffe fur Kinder und Jugendliche.
33867658 2021. Why are COVID-19 vaccines still in short supply?
33835769 2021. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
33835768 2021. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
33826816 2021. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
33882219 2021. Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
33861525 2021. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
33861524 2021. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
33979486 2021. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
33270381 2021. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
33378609 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
33378607 2021. A New Vaccine to Battle Covid-19.
33378605 2021. Maintaining Safety with SARS-CoV-2 Vaccines.
34099947 2021. Neuralgia amiotrofica secundaria a vacuna contra COVID-19 Vaxzevria (AstraZeneca).
34049738 2021. Recomendaciones diagnostico-terapeuticas del grupo de trabajo de expertos de FACME ad-hoc sobre el manejo de la trombosis venosa cerebral relacionada con la vacunacion frente a COVID-19.
33935343 2021. Sputnik V vaccine goes global.
33867618 2021. Covid-19 vaccines for kids.
33986292 2021. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation.
33986287 2021. Protein-based antigen presentation platforms for nanoparticle vaccines.
33986272 2021. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.
33972565 2021. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
33883557 2021. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases.
33875658 2021. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.
33863911 2021. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
33846340 2021. Force of infection: a determinant of vaccine efficacy?
33982646 2021. Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.
33915546 2021. Vaccinating People with Obesity for COVID-19: EASO Call for Action.
33830447 2021. COVID-19 Vaccines: Special Considerations for the Obese Population.
33370015 2021. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know.
33839780 2021. Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of Adenovirus Vector-Based COVID-19 Vaccines?
33933145 2021. Review the safety of Covid-19 mRNA vaccines: a review.
33828922 2021. Immunoinformatic approach to design a multiepitope vaccine targeting non-mutational hotspot regions of structural and non-structural proteins of the SARS CoV2.
33909687 2021. Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study.
33886573 2021. The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement.
33882114 2021. Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization.
34014316 2021. Bell's palsy following the Ad26.COV2.S COVID-19 vaccination.
33985514 2021. Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?
34058573 2021. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine.
33875266 2021. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
34020815 2021. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
34006408 2021. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
34049734 2021. Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
34023137 2021. Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
33339671 2021. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
33485647 2021. The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
33836897 2021. COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
33824043 2021. The development of COVID-19 vaccines in the United States: Why and how so fast?
33824042 2021. Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients.
33958223 2021. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
34067141 2021. Sensitivity to COVID-19 Vaccine Effectiveness and Safety in Shanghai, China.
34066475 2021. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
34066443 2021. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.
34063733 2021. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.
34063562 2021. Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein.
33925446 2021. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.
33923363 2021. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
33919151 2021. Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2.
33921677 2021. AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.
33923573 2021. Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles.
33923530 2021. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database.
33921215 2021. The C-Terminal Domain of Nef(mut) Is Dispensable for the CD8(+) T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles.
33916222 2021. Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials.
33916180 2021. A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.
33915773 2021. BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.
33915696 2021. Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.
33875919 2021. Los gobiernos y la vacunacion contra la COVID-19.
33867900 2021. Impacto de las variantes geneticas de la espicula en las vacunas frente al SARS-CoV-2.


34092181 2021. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
34003073 2021. Mining of linear B cell epitopes of SARS-CoV-2 ORF8 protein from COVID-19 patients.
33993845 2021. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
33890550 2021. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.
33913314 2021. Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG.
33939345 2021. Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected.
33855628 2021. Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement.
34095746 2021. COVID-19 vaccination may cause FDG uptake beyond axillary area.
33966930 2021. SARS-CoV-2 vaccines: Lights and shadows.
34092488 2021. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines.
34090750 2021. SARS-CoV-2 vaccine-induced cerebral venous thrombosis.
34001390 2021. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination.
33937467 2021. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases.
33898675 2021. New-onset chilblains in close temporal association to mRNA-1273 vaccination.
34056055 2021. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine.
33997209 2021. Widespread annular eruption after Ad26.COV2.S COVID-19 vaccine.
33958175 2021. Acute Coronary Tree Thrombosis After Vaccination for COVID-19.
33835172 2021. Public Perspectives on COVID-19 Vaccine Prioritization.
33892859 2021. Answering the call to action: rapid implementation of an in-center hemodialysis SARS-CoV-2 vaccination program.
33931226 2021. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy.
33887320 2021. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
33887318 2021. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
33887316 2021. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms.
33887315 2021. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.
33932459 2021. Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant.
33932458 2021. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination.
34087252 2021. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.
34081948 2021. ANCA glomerulonephritis after the Moderna COVID-19 vaccination.
34081947 2021. Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients.
34052236 2021. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".
34048824 2021. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
34033857 2021. Is COVID-19 vaccination unmasking glomerulonephritis?
34029554 2021. Occurrence of severe COVID-19 in vaccinated transplant patients.
34000278 2021. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine.
33992674 2021. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination.
33964312 2021. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.
34027513 2021. Can integrated post-exposure vaccination against SARS-COV2 mitigate severe disease?
33895650 2021. Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty(R)).
33986431 2021. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
34023850 2021. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
33942763 2021. Unilateral lymphadenopathy after COVID-19 vaccination.
33975938 2021. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
33966881 2021. Antecedentes personales y vacunales como factores asociados a la infeccion por SARS-CoV-2.
33836858 2021. La vacunacion de la COVID-19.
34092400 2021. Hemorragias acrales tras la administracion de la segunda dosis de la vacuna contra el SARS-CoV-2. inverted question markUna reaccion posvacunal?
34034917 2021. Reflexiones medico-legales, eticas y deontologicas de la vacunacion de COVID-19 en profesionales sanitarios.
33317876 2021. Relacion entre la gravedad de la infeccion Covid-19 y el estado vacunal. Resultados de una encuesta anonima entre medicos de atencion primaria.
33942804 2021. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections.
33900279 2021. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).
33952256 2021. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice.
34022375 2021. Development of leading first-generation vaccines against SARS-CoV-2.
34065996 2021. An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters.
33851711 2021. Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria.
33956784 2021. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
33956782 2021. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged >/=65 Years - United States, January-March 2021.
33956781 2021. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.
34043615 2021. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.
34058986 2021. Heterologous vaccine interventions: boosting immunity against future pandemics.
34022793 2021. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
33840183 2021. Gender differences in vaccine therapy: where are we in COVID-19 pandemic?
33856242 2021. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
34049216 2021. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.
33990054 2021. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
33883063 2021. B cell therapy and the use of RNA-based COVID-19 vaccines.
33951374 2021. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
33852795 2021. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
33826815 2021. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
33882218 2021. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
33826819 2021. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
33951357 2021. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
34010526 2021. Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents.
34043894 2021. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
33730471 2021. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
34075212 2021. SARS-CoV-2 variants, spike mutations and immune escape.
34025046 2021. Impfung gegen SARS-CoV-2 bei Krebspatienten.
33936526 2021. A Data Driven Approach for Prioritizing COVID-19 Vaccinations in the Midwestern United States.
34056031 2021. SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision.
34076928 2021. COVID-19 vaccination in pediatric solid organ transplant recipients-Current state and future directions.
33858942 2021. Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model.
34019911 2021. Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma.
33909239 2021. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
33986880 2021. Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases.
33871650 2021. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis.
33968285 2021. COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan.
33868525 2021. Unilateral axillary lymphadenopathy following COVID-19 vaccination: A case report and imaging findings.
34025885 2021. Myocarditis following COVID-19 vaccination.
33874733 2021. COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of.
33904778 2021. Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination.
33780329 2021. COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is Here.
33942008 2021. In vitro cell culture model of human nasal-associated lymphoid tissue (NALT) to evaluate the humoral immune response to SARS-CoV-2 spike proteins.
33372339 2021. Talk of the town in 2021: Covid-19 vaccines likely take centre stage.
34039746 2021. SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1.
34059617 2021. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.
34023862 2021. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern.
34006829 2021. COVID-19 vaccines: progress and understanding on quality control and evaluation.
33944967 2021. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA).
34022491 2021. Comorbid insomnia and sleep apnea (COMISA) as an additional risk factor for reduced response to the COVID-19 vaccination?
34104221 2021. Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
34104219 2021. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
34035836 2021. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
33898273 2021. Safety of COVID-19 vaccines administered in the EU: Should we be concerned?
33888416 2021. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine.
33971319 2021. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
34051352 2021. Emerging issues in COVID-19 vaccination in tropical areas: Impact of the immune response against helminths in endemic areas.
34013223 2021. Coronavirus infections in childhood and vaccine studies.
33925069 2021. Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach.
33847296 2021. Commentary: Perinatal Coronavirus Disease 2019 and Maternal Vaccination: What More Do We Need to Know?
34077949 2021. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine.
34088762 2021. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination.
34088761 2021. Myocarditis After SARS-CoV-2 Vaccination: True, True, and... Related?
33980697 2021. COVID-19 Vaccines in Children and Adolescents.
34049881 2021. Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.


33355178 2021. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
34029956 2021. Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination.
34007056 2021. SARS-CoV-2 vaccines: anamnestic response in previously infected recipients.
33321075 2021. Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets.
33928916 2021. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
33937733 2021. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
34095793 2021. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers.
33319186 2021. The challenges of distributing COVID-19 vaccinations.
33830018 2021. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.
33829462 2021. SARS-CoV-2 vaccine development: where are we?
33877041 2021. COVID-19 Vaccine Concerns: Fact or Fiction?
33896316 2021. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?
33929930 2021. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China.
33851875 2021. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies.
34095871 2021. SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility.
33901607 2021. SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats.
33996868 2021. COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities.
33968996 2021. Antibodies and Vaccines Target RBD of SARS-CoV-2.
33959636 2021. Impact of Ribosome Activity on SARS-CoV-2 LNP - Based mRNA Vaccines.
33937326 2021. Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.
33869282 2021. Perspectives on RNA Vaccine Candidates for COVID-19.
34035759 2021. Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.
34035758 2021. The Importance of Vaccinating IBD Patients During the COVID-19 Pandemic.
34048782 2021. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
34029569 2021. AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update.
34015337 2021. COVID-19 Vaccination and IBD: Desired antibody responses, future directions, and a note of caution.
33887219 2021. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.
34079091 2021. Gene therapy avenues and COVID-19 vaccines.
34040942 2021. WHF Position Statement on COVID Vaccination.
34080997 2021. Covid-19 vaccine trials and ethics: Protection delayed is protection denied.
34080991 2021. Emergency use authorisation of Covid-19 vaccines: An ethical conundrum.
34080989 2021. Covid-19 vaccines: The public must have confidence in the science.
33845947 2021. Covid-19 vaccines and new mutant strains impacting the pandemic.
33934742 2021. Effect of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccination in healthcare workers with high-risk coronavirus disease 2019 (COVID-19) exposure.
34039450 2021. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans' Affairs healthcare system.
33858531 2021. Coronavirus disease 2019 (COVID-19) vaccination in healthcare workers: An early real-world experience.
33853695 2021. An assessment of the impact of the vaccination program on coronavirus disease 2019 (COVID-19) outbreaks in care homes in Northern Ireland-A pilot study.
33932192 2021. Brief review of the mRNA vaccines COVID-19.
33898733 2021. Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2.
33895475 2021. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.
33907509 2021. Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces.
33907508 2021. mRNA vaccines for COVID-19: what, why and how.
33907443 2021. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study.
33872783 2021. First case of postmortem study in a patient vaccinated against SARS-CoV-2.
33897313 2021. Prediction of Epitope based Peptides for Vaccine Development from Complete Proteome of Novel Corona Virus (SARS-COV-2) Using Immunoinformatics.
33839230 2021. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
33964339 2021. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
33978550 2021. Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population.
34021862 2021. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights.
34100214 2021. Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?
34046690 2021. Impfstoffentwicklung zur Pravention von COVID-19 - Teil 3.
33355681 2021. Impfstoffentwicklung zur Pravention von COVID-19.
34041693 2021. Impact of first dose of BNT162b2 vaccine on COVID-19 infection among healthcare workers in an Irish hospital.
33960748 2021. SARS-CoV-2 vaccines and biological treatments: dermatological perspectives.
33960747 2021. Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST).
34087242 2021. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
34052265 2021. Optimizing investigation of suspected allergy to polyethylene glycols.
33857566 2021. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines.
34033981 2021. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome.
34051613 2021. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.
34020254 2021. Perspectives on vaccine induced thrombotic thrombocytopenia.
33984571 2021. A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine.
34098950 2021. Identification of COVID-19 B-cell epitopes with phage-displayed peptide library.
34038700 2021. Engineering a multi epitope vaccine against SARS-CoV-2 by exploiting its non structural and structural proteins.
34032357 2021. Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient.
33325143 2021. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
34048910 2021. Randomized COVID-19 vaccination rollout can offer direct real-world evidence.
33974565 2021. What should define a SARS-CoV-2 "breakthrough" infection?
33956667 2021. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19.
33939647 2021. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
33945504 2021. Is complement the culprit behind COVID-19 vaccine-related adverse reactions?
34101623 2021. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.
34101621 2021. The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: considering maternal and neonatal benefits.
33918932 2021. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure.
33916020 2021. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic.
34007358 2021. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
34077622 2021. Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine.
33941502 2021. COVID-19 vaccine prioritisation for people with cystic fibrosis.
34077690 2021. COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals.
34062184 2021. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination.
33933530 2021. Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre.
33852930 2021. Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: A case series in a geriatric rehabilitation ward during an outbreak.
34052241 2021. Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.
34044037 2021. Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
34060264 2021. Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.
34060261 2021. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
33942579 2021. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
33942578 2021. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
33975397 2021. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
33876589 2021. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
33847085 2021. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
34040784 2021. We should not vaccinate the young to protect the old: a response to Giubilini, Savulescu, and Wilkinson.
33967342 2021. In silico identification of RBD subdomain of spike protein from Pro(322)-Thr(581) for applications in vaccine development against SARS-CoV2.
33632278 2021. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.
34050904 2021. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
33342640 2021. COVID-19 Vaccines for Children: The Essential Role of the Pediatric Nurse.
34035689 2021. Importance of Pediatric Studies in SARS-CoV-2 Vaccine Development.
33912506 2020. The COVID-19 Vaccine Saga: A Perspective.
33993119 2021. Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases.
34057463 2021. High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients.
33999200 2021. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls.
34109386 2021. Myositis ossificans following COVID-19 vaccination.
34109037 2021. The trade-off between mobility and vaccination for COVID-19 control: a metapopulation modelling approach.
34108440 2021. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines.
33991580 2021. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy.
34042415 2021. Phageome-based vaccination and human innate immune modulation could be a useful strategy to control human Coronavirus infections.
33377359 2021. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
33998976 2021. COVID-19 vector-based vaccine causing thrombosis.
34089016 2021. Six months of COVID vaccines: what 1.7 billion doses have taught scientists.
34038554 2021. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium.
33944757 2021. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
33833104 2021. Latest Russian vaccine comes with a big dose of mystery.


33958344 2021. Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination.
34060379 2021. An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.
34036839 2021. Spotlight on Adenovirus-Based Vaccines and Rare Thrombotic Events.
33872607 2021. Methods matter - Tailoring SARS-CoV-2 antibody targets to vaccination status.
33857476 2021. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers.
33838977 2021. Re: Unilateral axillary adenopathy in the setting of COVID-19 vaccine, Clinical Imaging, January 2021.
33932618 2021. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation.
34089859 2021. Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus.
33949653 2021. COVID-19 Vaccines Have Moved Out of Neutral, but Still Gearing Up in Children.
33704435 2021. Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening.
33977301 2021. Adults Hospitalized With Coronavirus Disease 2019 (COVID-19)-United States, March-June and October-December 2020: Implications for the Potential Effects of COVID-19 Tier-1 Vaccination on Future Hospitalizations and Outcomes.
33825869 2021. Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents.
33825859 2021. SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2.
33975007 2021. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
33957273 2021. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
33928459 2021. Coronavirus disease 2019 (COVID-19) vaccination in systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody-associated vasculitis.
34045122 2021. COVID-19 Vaccine Effectiveness.
34039479 2021. Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic.
33832783 2021. The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World.
34007835 2021. PET findings after COVID-19 vaccination: "Keep Calm and Carry On".
33841880 2021. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.
34047471 2021. Identification of potential vaccine targets for COVID-19 by combining single-cell and bulk TCR sequencing.
33980499 2021. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
34001557 2021. Grossesse, allaitement et vaccin contre le SRAS-CoV-2 : cadre ethique pour la prise de decision partagee.
33990339 2021. Limb ischemia and pulmonary artery thrombosis afer the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia.
33936564 2021. An overview of current COVID-19 vaccine platforms.
33845870 2021. Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19.
33834172 2021. Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Action.
33968543 2021. A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine.
33927933 2021. COVID-19 Vaccine and Hyperosmolar Hyperglycemic State.
33867863 2021. Status Report on COVID-19 Vaccines Development.
34073214 2021. Ethical Considerations in Chemotherapy and Vaccines in Cancer Patients in Times of the COVID-19 Pandemic.
34093062 2021. Opportunities for innovation: Building on the success of lipid nanoparticle vaccines.
33906124 2021. Future considerations for the mRNA-lipid nanoparticle vaccine platform.
34049261 2021. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.
33969163 2021. Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia.
33918702 2021. Immune Response Visualized In Vivo by [18F]-FDG PET/CT after COVID-19 Vaccine.
33941488 2021. Italian association for the study of the liver position statement on SARS-CoV2 vaccination.
33963055 2021. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
33993619 2021. Steroid-Resistant Acute Cellular Rejection of the Liver After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination.
34098108 2021. Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo.
33983745 2021. The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine.
33352107 2021. Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA.
34091054 2021. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNP.
34015254 2021. Low-dose single-shot COVID-19 mRNA vaccines lie ahead.
33895322 2021. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
33684280 2021. Neutralizing Activity of BNT162b2-Elicited Serum.
33973802 2021. How has nanomedical innovation contributed to the COVID-19 vaccine development?
34001897 2021. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.
34103510 2021. Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination.
33824489 2021. Emerging concepts in the science of vaccine adjuvants.
33927376 2021. Will SARS-CoV-2 variants of concern affect the promise of vaccines?
33340022 2021. Viral targets for vaccines against COVID-19.
33868742 2021. Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials.
33944946 2021. COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.
33895831 2021. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort.
33839785 2021. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study.
33907627 2021. Is the heparin-induced thrombocytopenia-like syndrome associated with ChAdOx vaccine related to the vaccine itself or to an autoimmune reaction to severe acute respiratory syndrome 2 coronavirus: insights and implications from previous reports in infected cases?
34092876 2021. Is it safe to breastfeed my baby after a coronavirus vaccine?
34024981 2021. Are booster shots coming?
34069575 2021. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.
33923054 2021. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
34075293 2021. Expediting COVID-19 vaccination increases QALYs and saves costs in the USA.
33882066 2021. Evaluation of COVID-19 vaccination strategies with a delayed second dose.
33956791 2021. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK.
34043618 2021. DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss.
33906339 2021. Vacunacion anti-COVID-19: La realidad tras los ensayos clinicos.
33913444 2021. Efectividad de la primera dosis de vacuna BNT162b2 para prevenir la COVID-19 en personal sanitario.
33848321 2021. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
33858945 2021. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination.
33828130 2021. Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework.
34072058 2021. SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center.
34071883 2021. Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism.
34073382 2021. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects.
34070671 2021. Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals.
33843419 2021. Women perception of SARS-CoV-2 vaccination during pregnancy and subsequent maternal anxiety: a prospective observational study.
33840294 2021. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
33843975 2021. SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women.
33974012 2021. Even Partial COVID-19 Vaccination Protects Nursing Home Residents.
33956050 2021. Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce.
33956048 2021. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
33929487 2021. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
33983379 2021. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
33950155 2021. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
34037666 2021. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
33315080 2021. The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.
33315069 2021. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
33978670 2021. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
33999120 2021. Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos.
33904857 2021. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database.
33897043 2021. Note of the Congregation for the Doctrine of the Faith on the morality of using some anti-Covid-19 vaccines, 21.12.2020.
33836419 2021. Are prion proteins and magnetite involved in the immune cells memory system connected to the covid-19?
33976102 2021. In brief: Johnson & Johnson COVID-19 vaccine suspended.
33976095 2021. In brief: Suspension of Johnson & Johnson COVID-19 vaccine lifted.
33976088 2021. FDA authorizes Johnson & Johnson COVID-19 vaccine.
34080537 2021. COVID-19, des vaccins a la vitesse de l'eclair.
33295677 2021. Prediction of putative epitope-based vaccine against all corona virus strains for the Chinese population: Approach toward development of vaccine.
33882227 2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
33882226 2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
33979495 2021. Audio Interview: Vaccination and Variants in the U.S. and South Africa.
34077642 2021. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply.
34077641 2021. Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
34077640 2021. Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
33979508 2021. More on SARS-CoV-2 Infection after Vaccination in Health Care Workers. Reply.
33979507 2021. More on SARS-CoV-2 Infection after Vaccination in Health Care Workers.
33277624 2021. COVID-19 vaccines buoy hope.
34021284 2021. Scientists zero in on long-sought marker of COVID-vaccine efficacy.
34002079 2021. COVID vaccines can block variant hitting Asia, lab study finds.
33986508 2021. Delaying a COVID vaccine's second dose boosts immune response.
33976411 2021. Mice with severe COVID symptoms could speed vaccine effort.
33971664 2021. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
34044428 2021. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.


34021048 2021. Influenza Virus and SARS-CoV-2 Vaccines.
33972374 2021. Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.
33873199 2021. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
33260195 2021. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
33927405 2021. Can Cuba beat COVID with its homegrown vaccines?
33864047 2021. Coronapod: could COVID vaccines cause blood clots? Here's what the science says.
34097667 2021. COVID-19 Vaccination Outcomes at a Pediatric Long-Term Care Facility.
33998197 2021. Innocuite du vaccin a ARNm Covid-19 chez les femmes enceintes : resultats preliminaires.
33830701 2021. Vaccins contre le Covid-19 : cibles vaccinales, immunogenicite et reactions allergiques.
33852214 2021. Reponses immunes a une dose de vaccin administree apres un Covid.
33896793 2021. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on vaccine safety on AstraZeneca COVID-19 vaccine.
33766863 2021. New problems erode confidence in AstraZeneca's vaccine.
33766861 2021. Volatility of vaccine confidence.
33915005 2021. SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients.


33893480 2021. First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection.
33953551 2021. Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist.
33930764 2021. Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine against the SARS-CoV-2 new variants, and its validation through in silico cloning and immune simulation.
33895459 2021. Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study.
33969180 2021. First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization.
33993417 2021. Mucosal and transdermal vaccine delivery strategies against COVID-19.
33826439 2021. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
33976529 2021. COVID-19 vaccination in pregnancy.
33913552 2021. Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient.
33913545 2021. Herpes zoster emergence following mRNA COVID-19 vaccine.
33851735 2021. Bioinformatics and immunoinformatics to support COVID-19 vaccine development.
33822361 2021. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
33788281 2021. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
33882225 2021. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
34007070 2021. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
33864052 2021. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
34040262 2021. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
33675239 2021. Nucleoside-modified messenger RNA COVID-19 vaccine platform.
33973833 2021. Mass population vaccination for COVID-19 in Malta.
34014263 2021. Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data.
34086047 2021. Children and COVID-19 Vaccines.
33975372 2021. Eine akute Fazialisparese als mogliche Impfkomplikation bei einer Impfung gegen SARS-CoV-2.
34044465 2021. COVID-19-Impfungen: Replizierend oder Nichtreplizierend?
33909962 2021. Beyond the First Dose - Covid-19 Vaccine Follow-through and Continued Protective Measures.
33826826 2021. Audio Interview: Antibody Responses to Natural Infection and Vaccination.
33913647 2021. Audio Interview: Advice for Clinicians on Covid-19 Vaccines and Social Restrictions.
33761227 2021. Leveraging Open Science to Accelerate Research.
33882211 2021. Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.
33852785 2021. Audio Interview: Vaccine Successes and Vaccine Adverse Events.
33927434 2021. Challenge for COVID-19 vaccines to protect the New Zealand population.
34032435 2021. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
34060925 2021. Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
33981074 2021. A network analysis of COVID-19 mRNA vaccine patents.
34059823 2021. After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
33903751 2021. Being fair to participants in placebo-controlled COVID-19 vaccine trials.
33888900 2021. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
33875890 2021. COVID-19 dynamics after a national immunization program in Israel.
33335323 2021. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
33335322 2021. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
33927396 2021. COVID-19 vaccine and blood clotting.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis